The pleiotropic of GLP-1/GLP-1R axis in central nervous system diseases

被引:24
作者
Zhang, LongQing [1 ]
Zhang, Wen [1 ]
Tian, XueBi [1 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Anesthesiol, Wuhan, Hubei, Peoples R China
基金
中国国家自然科学基金;
关键词
GLP-1; GLP-1R; CNS diseases; neuroprotection; GLUCAGON-LIKE PEPTIDE-1; BLOOD-BRAIN-BARRIER; GLP-1 RECEPTOR AGONIST; SPINAL-CORD-INJURY; MPTP MOUSE MODEL; CLOZAPINE-ASSOCIATED OBESITY; ALCOHOL-MEDIATED BEHAVIORS; PARKINSONS-DISEASE; HEMORRHAGIC TRANSFORMATION; SYNAPTIC PLASTICITY;
D O I
10.1080/00207454.2021.1924707
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Glucagon-like peptide-1(GLP-1) is a multifunctional polypeptide throughout the lifespan via activating Glucagon-like peptide-1 receptor (GLP-1R).GLP-1 can affect food ingestion, enhance the secretion of insulin from pancreatic islets induced by glucose and be utilized to treat type 2 diabetes mellitus(T2DM).But, accumulating evidences from the decades suggest that activation GLP-1R can not only regulate the blood glucose, but also sustain the homeostasis of intracellular environment and protect neuron from various damaged responses such as oxidative stress, inflammation, excitotoxicity, ischemia and so on. And more and more pre-clinical and clinical studies identified that GLP-1 and its analogues may play a significant role in improving multiple central nervous system (CNS) diseases including neurodegenerative diseases, epilepsy, mental disorders, ischemic stroke, hemorrhagic stroke, traumatic brain injury, spinal cord injury, chronic pain, addictive disorders, other diseases neurological complications and so on. In order to better reveal the relationship between GLP-1/GLP-1R axis and the growth, development and survival of neurons, herein, this review is aimed to summarize the multi-function of GLP-1/GLP-1R axis in CNS diseases.
引用
收藏
页码:473 / 491
页数:19
相关论文
共 186 条
  • [1] Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease
    Abbas, Talib
    Faivre, Emilie
    Hoelscher, Christian
    [J]. BEHAVIOURAL BRAIN RESEARCH, 2009, 205 (01) : 265 - 271
  • [2] Lixisenatide, a novel GLP-1 analog, protects against cerebral ischemia/reperfusion injury in diabetic rats
    Abdel-latif, Rania G.
    Heeba, Gehan H.
    Taye, Ashraf
    Khalifa, Mohamed M. A.
    [J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2018, 391 (07) : 705 - 717
  • [3] Effect of glucagon-like peptide-1 analogue; Exendin-4, on cognitive functions in type 2 diabetes mellitus; possible modulation of brain derived neurotrophic factor and brain Visfatin
    Abdelwahed, O. M.
    Tork, O. M.
    el Din, M. M. Gamal
    Rashed, L.
    Zickri, M.
    [J]. BRAIN RESEARCH BULLETIN, 2018, 139 : 67 - 80
  • [4] Protective effect of N-glycan bisecting GlcNAc residues on β-amyloid production in Alzheimer's disease
    Akasaka-Manya, Keiko
    Manya, Hiroshi
    Sakurai, Yoko
    Wojczyk, Boguslaw S.
    Kozutsumi, Yasunori
    Saito, Yuko
    Taniguchi, Naoyuki
    Murayama, Shigeo
    Spitalnik, Steven L.
    Endo, Tamao
    [J]. GLYCOBIOLOGY, 2010, 20 (01) : 99 - 106
  • [5] GLP-1 Neurons in the Nucleus of the Solitary Tract Project Directly to the Ventral Tegmental Area and Nucleus Accumbens to Control for Food Intake
    Alhadeff, Amber L.
    Rupprecht, Laura E.
    Hayes, Matthew R.
    [J]. ENDOCRINOLOGY, 2012, 153 (02) : 647 - 658
  • [6] GLP-1 is both anxiogenic and antidepressant; divergent effects of acute and chronic GLP-1 on emotionality
    Anderberg, Rozita H.
    Richard, Jennifer E.
    Hansson, Caroline
    Nissbrandt, Hans
    Bergquist, Filip
    Skibicka, Carolina P.
    [J]. PSYCHONEUROENDOCRINOLOGY, 2016, 65 : 54 - 66
  • [7] Araki Y, 2002, INT J MOL MED, V9, P53
  • [8] Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease
    Argaw, Azeb Tadesse
    Asp, Linnea
    Zhang, Jingya
    Navrazhina, Kristina
    Trinh Pham
    Mariani, John N.
    Mahase, Sean
    Dutta, Dipankar J.
    Seto, Jeremy
    Kramer, Elisabeth G.
    Ferrara, Napoleone
    Sofroniew, Michael V.
    John, Gareth R.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2012, 122 (07) : 2454 - 2468
  • [9] Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia
    Asahi, M
    Wang, XY
    Mori, T
    Sumii, T
    Jung, JC
    Moskowitz, MA
    Fini, ME
    Lo, EH
    [J]. JOURNAL OF NEUROSCIENCE, 2001, 21 (19) : 7724 - 7732
  • [10] Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial
    Athauda, Dilan
    Maclagan, Kate
    Skene, Simon S.
    Bajwa-Joseph, Martha
    Letchford, Dawn
    Chowdhury, Kashfia
    Hibbert, Steve
    Budnik, Natalia
    Zampedri, Luca
    Dickson, John
    Li, Yazhou
    Aviles-Olmos, Iciar
    Warner, Thomas T.
    Limousin, Patricia
    Lees, Andrew J.
    Greig, Nigel H.
    Tebbs, Susan
    Foltynie, Thomas
    [J]. LANCET, 2017, 390 (10103) : 1664 - 1675